Janux Therapeutics (JANX) Revenue (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of Revenue data on file, last reported at $3.7 million in Q1 2026.

• Quarterly Revenue changed N/A year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.7 million (up 47.1% YoY) and the FY2025 annual result came in at $10.0 million, down 5.55% from the prior year.
• Revenue declined to $3.7 million in Q1 2026 per JANX's latest filing, from $10.0 million in the prior quarter.
• Across five years, Revenue topped out at $10.0 million in Q3 2025 and bottomed at $439000.0 in Q3 2024.
• The 5-year median for Revenue is $2.4 million (2022), against an average of $3.2 million.
• The widest annual swing landed in 2024, when Revenue plunged 82.56%; it then surged 2177.9% in 2025.
• Tracing JANX's Revenue over 5 years: stood at $2.8 million in 2022, then fell by 13.5% to $2.5 million in 2023, then sank by 82.16% to $439000.0 in 2024, then surged by 2177.9% to $10.0 million in 2025, then tumbled by 62.67% to $3.7 million in 2026.
• Per Business Quant, the three latest JANX Revenue figures stand at $3.7 million (Q1 2026), $10.0 million (Q3 2025), and $439000.0 (Q3 2024).

Peer Comparison